WO2004064810A1 - 口腔内速崩性錠剤 - Google Patents
口腔内速崩性錠剤 Download PDFInfo
- Publication number
- WO2004064810A1 WO2004064810A1 PCT/JP2004/000444 JP2004000444W WO2004064810A1 WO 2004064810 A1 WO2004064810 A1 WO 2004064810A1 JP 2004000444 W JP2004000444 W JP 2004000444W WO 2004064810 A1 WO2004064810 A1 WO 2004064810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- bran
- hydrochloride
- starch
- rapidly disintegrating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to an orally rapidly disintegrating tablet which has a practically sufficient hardness and which disintegrates quickly in a roll.
- hardness that has no practical problem usually means a hardness of 35 N or more.
- Failure quickly means that it usually collapses within one minute.
- bran alcohol such as mantoxyl xylitol
- bran alcohol is liable to cause such problems as sticking (sticking to punches) and binding (sticking to mortar) during tableting, and it is difficult to secure hardness. Therefore, when manufacturing a rapidly disintegrating tablet in the mouth using sugar alcohol as an excipient, for example, a mixture containing bran alcohol is first moistened with appropriate moisture, compression molded at a low pressure, and then dried. Special manufacturing methods and special equipment for locking have been adopted.
- Patent Document 1 International Patent Publication No. WO 97/472 787 Pan fret
- Patent Document 2 Japanese Patent Application Laid-Open No. 2001-58984
- An object of the present invention is to provide a tablet that can be easily and easily produced by a normal tablet manufacturing method including a tableting machine to be used without any problem, has a practically satisfactory hardness, and rapidly disintegrates in the oral cavity.
- the present invention provides a rapidly disintegrating tablet in the mouth.
- the present inventors have conducted a thorough study and found that the above-described object can be achieved by tablet-forming a coated granule in which a core made of a granule containing a drug is coated with a disintegrant for pharmaceutical preparations.
- the present inventors have found that a rapidly disintegrating tablet in the oral cavity can be obtained, and have completed the present invention.
- the present invention provides a coated granule in which a core made of a granulated substance containing a water-soluble drug or a core made of a granulated substance containing a medicine and bran is coated with a disintegrant for pharmaceutical preparations.
- a rapidly disintegrating buccal tablet (hereinafter, referred to as "tablet of the present invention") characterized by being manufactured by tableting the product.
- the ⁇ saccharide '' that can be used in the present invention is not particularly limited as long as it is a pharmaceutically acceptable saccharide; for example, mannitol, xylitol, sorbitol, erythritol tonole, maltitol, Examples thereof include bran alcohol typified by maltose, milk bran, sucrose, glucose, and oligo bran. One or more of these can be used. In particular, mannitol and lactose are preferable, and it is also preferable to use mannitol and lactose in combination.
- a ⁇ disintegrant for pharmaceutical preparations '' that can be used in the present invention is a pharmaceutically acceptable excipient that can promote the disintegration or dispersion of tablets into secondary particles or individual particles in saliva.
- the disintegrant is not particularly limited as long as it is a disintegrant used in pharmaceutical preparations, and examples thereof include a crystalline cell mouth, a low-substituted hydroxypropylcellulose, and a force / repoxymethinoresenolerose (force / reme).
- Canolepoxime chinorecellulose calcium (carmellose calcium), crospovidone; or potato starch, wheat starch, corn starch, med starch, hydroxypropyl pilstarch (HPS), partially lipoxymethyl acetyl starch Starches represented by (PCS) can be mentioned. One or more of these can be used. Particularly, corn starch is preferred.
- the average particle size of the S. granulated product according to the present invention is not particularly limited, but when a low- or low-water-soluble drug is used, 20 to: L000 / m is appropriate, and 30 to 500 m, more preferably 50-200 / xm. The smaller the particle size, the better.
- the drug is not particularly limited, and examples thereof include the following drugs.
- water-soluble drug refers to water at 20 ° C.
- Diphedipine isosorbit dinitrate, diltiazem hydrochloride, trapidil, dipyridamole, m-dilazep, methyl 2,6
- Diprofilin Sulftamol sulfate, chlorprenalin hydrochloride, fonoremoterinol fumanoleate, orciprenaline sulfate, pirpterol hydrochloride, hexoprenaline sulfate, bitolterol mesylate Clembuterol hydrochloride, terbutaline sulfate, mabuterol hydrochloride, penoterol hydrobromide., Methoxifen hydrochloride.
- Proforce hydrochloride Inamid, disopyramide, azimarin, quinine sulfate, aplidine hydrochloride, propafunnon hydrochloride, mexiletine hydrochloride.
- Fututoin sodium pulp pulp, metal bital, dynamazepine.
- Glibengramide tolptamide, grimidine sodium, triglitazone, mouth siglitazone, pioglitazone hydrochloride, epallestact ⁇
- the mixing ratio of the drug and the bran in “the granulated product containing the drug and the sugar” is 0.3 to 1000 parts by weight per 1 part of the drug, and 0.6 to 0.6 parts by weight. 500 parts are preferred.
- the amount of the disintegrant for pharmaceutical preparations varies depending on the particle size of the nucleus, and is not particularly limited as long as the nucleus is coated.However, too much affects the moldability and ingestibility.
- the amount coated on the surface is preferable.
- J whose core is covered with a disintegrant for pharmaceutical preparations means a state in which the disintegrant for pharmaceutical preparations is fixed to almost the entire surface of the core. It can be set appropriately according to the dosage of the drug to be applied.
- a third Additives can be appropriately compounded.
- additives include, for example, fluidizers, lubricants, coloring agents, fragrances, adsorbents, stabilizers, antioxidants, ⁇ > H regulators, surfactants, buffers, and flavors It can contain additives such as sweeteners, sweeteners, foaming agents, preservatives, sour agents, and fresheners as needed.
- fluidizing agents examples include long-chain fatty acids such as stearic acid; monoglycerides, diglycerides, and triglycerides of long-chain (C10-22) fatty acids; carnapalous, polyoxy
- long-chain fatty acids such as stearic acid
- examples include ethylene-hardened castor oil, high-grade fatty alcohols such as stearyl alcohol, and waxes such as cetanol; lecithin and sodium lauryl sulfate.
- stearic acid monoglycerides, diglycerides, and triglycerides of long-chain (C10-22) fatty acids
- examples include ethylene-hardened castor oil, high-grade fatty alcohols such as stearyl alcohol, and waxes such as cetanol; lec
- Lubricants include, for example, stearate, magnesium stearate, aluminum stearate, aluminum monostearate, calcium stearate, stearyl alcohol, talc, titanium oxide, light titanium oxide ⁇
- Water silicic acid, hydrated silicon dioxide, magnesium silicate, synthetic aluminum silicate, calcium hydrogen phosphate, succinic fatty acid ester, hydrogenated castor oil, hydrogenated rapeseed oil, carnauba wax, beeswax, corn starch examples thereof include polyethylene glycol, microcrystalline detergent, sodium sodium lauryl sulfate, and they can be contained in the tablet of the present invention at, for example, 3% by weight or less.
- coloring agent examples include iron sesquioxide, yellow iron sesquioxide, titanium oxide ', and tartarium oxide.
- the coloring agent can be contained, for example, at 1% by weight or less.
- the fragrance examples include fennel oil, orange oil, caffeine oil, cinnamon oil, turpentine oil, hearth oil, coconut oil, and lemon oil.
- the tablet of the present invention for example, 3% by weight The following can be contained.
- adsorbents include light caustic anhydride, calcium silicate, calcium phosphate anhydride, gum, precipitated calcium carbonate, and stabilizers such as cyclodextrin, Sodium edetate and antioxidants include, for example, tocopherol, ascorbic acid, and sodium hydrochloride.
- stabilizers such as cyclodextrin, Sodium edetate and antioxidants include, for example, tocopherol, ascorbic acid, and sodium hydrochloride.
- sine and pH regulators include phosphate, acetate, carbonate, tate, tartrate, fumarate, aminoate, and surfactants.
- a buffer for example, ascorbic acid, sodium chloride, potassium chloride, sodium carbonate, and as a flavoring agent, lactose, shiranuka, pudanuka, mannetol
- sweeteners include: , Saccharinna Lithium, aspartame, nicotine glycyrrhizinate, stevia (sucrose), and foaming agents include, for example, sodium hydrogen carbonate, potassium hydrogen carbonate, and preservatives.
- benzoate, paraoxybenzoate, salicylate, sodium edetate, and sour agents include, for example, citric acid, tartaric acid, and malic acid.
- ascorbic acid and fresheners include menthol, heart-shaped oil, caffeine oil, wicket oil, and camphor.
- the dosage form of the tablet of the present invention is not particularly limited, such as, for example, circular, oval, and donut-shaped irregular forms. Divided tablets can also be used.
- the thickness of the tablet is not particularly limited, but a thickness of 1 to 10 mm is appropriate, and a thickness of 2 to 8 mm is preferable. Generally, the thinner the tablet, the better the quick disintegration.
- the size of the tablet is not particularly limited, for example, a short diameter (diameter in case of a circular tablet) of 6 to 20 mm is suitable, and 8 to 12 mm is preferable.
- the tablet of the present invention can be obtained, for example, by coating a core made of a granulated product containing a drug with a disintegrant for pharmaceutical preparations by a conventional method using, for example, a fluidized-bed granulator and drying.
- the coated granules can be produced by tableting in a conventional manner.
- the core or medicine consisting of granules containing water-soluble medicine and bran can be produced, for example, by granulating and drying the raw materials such as a medicine and bran by a conventional method.
- a granulation dryer include a fluidized granulation dryer and a tumbling fluidized granulator dryer.
- the coating with the disintegrant for pharmaceutical preparations can be performed after the core is manufactured, but the granulation and drying can be performed continuously and continuously while the core is manufactured.
- a pharmaceutically acceptable binder can be added for the purpose of facilitating the binding between the core and the disintegrant for pharmaceutical preparations. It is preferred to add it.
- the binder is not particularly limited as long as it is used in pharmaceutical preparations. Specific examples include starch paste, methylcellulose, hydroxypropylcellulose (HPC-SSL, HPG-SL, HPC-L, etc.), hydroxypropylmethylcellulose, sodium propyloxymethylcellulose (carme (Rosin sodium), gum arabic, gelatin, agar, tragacanth, sodium alginate, pullulan, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene render alcohol. One or more of these can be used. Particularly, hydroxypropyl cellulose is preferred.
- saccharides such as lactose can also be added to the binder.
- the binder can be added in a solution state or a slurry state.
- the method for mixing the components is not particularly limited, and examples thereof include a method using a conventional mixer.
- the tableting method is not particularly limited, and examples thereof include a method using a conventional rotary tableting machine, a hydraulic press, and a single-shot tableting machine.
- the compression pressure for tableting is basically the same as the pressure for tablet production and is suitably in the range of 3 to 25 kN / cm2, preferably in the range of 8 to 17 kN / cm2.
- the tablet of the present invention can be produced even if it is less than 3 fcN / cm 2 or more than 25 kN / cm 2 , but the tableting pressure is too low. And tablet hardness may not be obtained. On the other hand, if it is too high, tablets that are difficult to disintegrate quickly in the oral cavity may be obtained.
- corn starch manufactured by Nippon Food Processing Co., Ltd.
- 45 g was gradually added into the granulation layer, and the core was coated with corn starch, and the coated granules were obtained through a drying process.
- 300 g of the granulated product is mixed with 1.5 g of magnesium stearate (Taira Chemical Co., Ltd .; the same applies hereinafter), and the mixture is compressed into tablets at 300 mg per tablet (Kikusui Seisakusho: Collect 12HUK: The tablet of the present invention having a compression pressure of 14.98 kN / cm ⁇ (l 49.8 MPa) (the same applies hereinafter)) and a tablet diameter of 10 mm ⁇ was obtained.
- Purified water containing 4.5 g of hydroxypropylcellulose and 9 g of milk bran was charged to a fluidized-bed granulator and dried with 6 g of illsogladine maleate, 225 g of D-mannitol and 159 g of milk bran.
- Granulation was performed by spraying 121.5 g, and when the binder solution became 1--3, 5 g of hydroxypropyl starch (HPS101, manufactured by Freund Corporation) was gradually added into the granulation layer.
- the coated granules were obtained through a drying process. 300 g of such granules
- the mixed powder to which 1.5 g of magnesium stearate was added was tableted to give 300 mg per tablet to obtain a tablet of the present invention having a tablet diameter of 10 ⁇ .
- 390 g of D-mannitol was charged into a fluidized bed granulation dryer, and hydroxyp Granulation is performed by spraying 121.5 g of purified water (binder solution) containing 4.5 g of mouth pill cellulose and 9 g of milk bran. When the binder solution becomes 1/3 remaining, corn starch '45 g is produced. It was gradually added into the granular layer, and dried to obtain a granulated product.
- a mixed powder obtained by adding 3 g of magnesium stearate to 300 g of the granulated product was tableted so as to give 300 mg per tablet to obtain a tablet of the present invention having a tablet diameter of 10 mm ⁇ .
- a coated granulated product was obtained through a drying process, and a mixed powder obtained by adding 3 g of magnesium stearate to 300 g of the granulated product was compressed into tablets at a ratio of 300 mg per tablet.
- a tablet of the present invention having a diameter of 10 mm was obtained.
- acetaminophen 60 g of D-mannitol, and 105 g of milk bran were placed in a fluidized bed granulator and purified water containing 4.5 g of hydroxypropyl cell mouth and 9 g of lactose ( Spray granules by spraying 121.5 g, and when the binder solution becomes 1/3 remaining, gradually add 45 g of cornstarch into the granulation layer, and coat and granulate through the drying process. I got something.
- a mixed powder obtained by adding 3 g of magnesium stearate ′ to 300 g of the granulated product was tableted so as to give 300 mg per tablet, thereby obtaining a tablet of the present invention having a tablet diameter of 10 ⁇ .
- a mixed powder obtained by adding 1.5 g of magnesium stearate to 300 g of the granulated product was tableted so as to give a tablet content of 300 mg per tablet, thereby obtaining a tablet of the present invention having a tablet diameter of 10 mm ⁇ .
- a mixed powder obtained by adding 6 g of illsogladine maleate, 225 g of D-mantol, 159 g of milk bran, 45 g of corn starch and 2.2 g of magnesium stearate is compressed into tablets at 300 mg per tablet.
- a comparative tablet having a tablet diameter of 10 mm ⁇ was obtained.
- Hardness The hardness was measured using a Monsanto hardness meter. Measure 10 tablets and show the average value.
- Disintegration time in disintegration test Disintegration time was confirmed based on the unmodified tablet in the disintegration test method of the Japanese Pharmacopoeia, 14th Edition, using the test solution as purified water.
- the tablet of the present invention could be produced satisfactorily without tableting trouble, had a practically acceptable hardness, and rapidly disintegrated in the oral cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/542,969 US8580305B2 (en) | 2003-01-21 | 2004-01-20 | Tablet quickly melting in oral cavity |
JP2005508095A JP4475233B2 (ja) | 2003-01-21 | 2004-01-20 | 口腔内速崩性錠剤 |
EP04703478A EP1595533B1 (en) | 2003-01-21 | 2004-01-20 | Tablet quickly melting in oral cavity |
DE602004024960T DE602004024960D1 (de) | 2003-01-21 | 2004-01-20 | Rasch in der mundhöhle schmelzende tablette |
AT04703478T ATE454132T1 (de) | 2003-01-21 | 2004-01-20 | Rasch in der mundhöhle schmelzende tablette |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003012357 | 2003-01-21 | ||
JP2003-012357 | 2003-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004064810A1 true WO2004064810A1 (ja) | 2004-08-05 |
Family
ID=32767327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000444 WO2004064810A1 (ja) | 2003-01-21 | 2004-01-20 | 口腔内速崩性錠剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8580305B2 (ja) |
EP (1) | EP1595533B1 (ja) |
JP (1) | JP4475233B2 (ja) |
KR (2) | KR101099176B1 (ja) |
AT (1) | ATE454132T1 (ja) |
DE (1) | DE602004024960D1 (ja) |
WO (1) | WO2004064810A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007052289A2 (en) * | 2005-07-22 | 2007-05-10 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
WO2007055428A1 (en) * | 2005-11-14 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Intraorally rapidly disintegrating tablet |
JP2007153887A (ja) * | 2005-11-14 | 2007-06-21 | Teijin Pharma Ltd | アンブロキソール口腔内速崩性錠剤 |
JP2008127320A (ja) * | 2006-11-20 | 2008-06-05 | Zensei Yakuhin Kogyo Kk | 口腔内速崩壊性固形製剤 |
WO2008120548A3 (ja) * | 2007-03-13 | 2008-12-18 | Dainippon Sumitomo Pharma Co | 口腔内崩壊錠 |
WO2009041651A1 (ja) | 2007-09-27 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | 速崩壊性固形製剤 |
JP2010095490A (ja) * | 2008-10-20 | 2010-04-30 | Nipro Corp | 錠剤の製造方法 |
JP2012046454A (ja) * | 2010-08-27 | 2012-03-08 | Lion Corp | 内服用錠剤およびその製造方法 |
JP5004236B2 (ja) * | 2005-02-09 | 2012-08-22 | キッセイ薬品工業株式会社 | 口腔内崩壊錠 |
WO2012144519A1 (ja) * | 2011-04-18 | 2012-10-26 | 出光興産株式会社 | 液体投与型粒剤 |
JP2013506683A (ja) * | 2009-10-01 | 2013-02-28 | アプタリス ファーマテク,インコーポレイテッド | 経口投与型コルチコステロイド組成物 |
WO2017115764A1 (ja) * | 2015-12-28 | 2017-07-06 | 日本新薬株式会社 | 圧縮成型製剤 |
US10105315B2 (en) | 2016-08-18 | 2018-10-23 | Adare Pharmaceuticals, Inc. | Methods of treating eosinophilic esophagitis |
JPWO2018003762A1 (ja) * | 2016-06-28 | 2019-04-18 | 株式会社日本抗菌総合研究所 | 賦形剤及び錠剤 |
US10471071B2 (en) | 2013-09-06 | 2019-11-12 | Adare Pharmaceuticals, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2533150C (en) * | 2003-07-25 | 2013-03-12 | Warner Chilcott Company, Inc. | A doxycycline metal complex in a solid dosage form |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20090208576A1 (en) * | 2006-03-31 | 2009-08-20 | Gandhi Anilkumar S | Orally Disintegrating Tablets |
WO2009002084A2 (en) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
KR101109633B1 (ko) | 2007-08-03 | 2012-01-31 | 제이더블유중외제약 주식회사 | 활성성분의 코팅막이 보호되는 구강내붕해제형을 제조하기위한 조성물 |
EP2641593A3 (en) * | 2008-02-28 | 2013-11-20 | AbbVie Inc. | Tablets |
KR101075556B1 (ko) * | 2008-11-21 | 2011-10-20 | 씨제이제일제당 (주) | 구강내 속붕해정 및 그 제조방법 |
SE533540C2 (sv) | 2008-12-19 | 2010-10-19 | Neoinvent Medical Engineering Ab | Administrerinssystem för administrering av en substans i munhålan |
EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
EP2314296A1 (en) * | 2009-10-22 | 2011-04-27 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally Disintegrating Tablets of Betahistine |
AU2011274845B2 (en) * | 2010-07-09 | 2015-07-30 | Teijin Limited | Orally disintegrating tablet |
DK2886108T4 (da) | 2013-12-23 | 2023-01-30 | Dr Falk Pharma Gmbh | Optimeret farmaceutisk formulering til behandling af inflammatoriske ændringer af øsofagus |
TWI695722B (zh) * | 2015-06-29 | 2020-06-11 | 日商大賽璐股份有限公司 | 固態製劑之外層用組成物及含有該外層用組成物之易服用性固態製劑 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0361874A2 (en) * | 1988-09-27 | 1990-04-04 | Takeda Chemical Industries, Ltd. | Granules having core and their production |
JPH08143473A (ja) * | 1994-11-22 | 1996-06-04 | Tanabe Seiyaku Co Ltd | 易服用性の有核錠型製剤 |
JP2001039861A (ja) * | 1999-07-30 | 2001-02-13 | Eisai Co Ltd | 薬物の放出を制御した速崩錠及びその製法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
DE69901938T3 (de) * | 1998-03-06 | 2012-08-02 | Aptalis Pharma S.R.L. | Schnell zerfallende tablette |
US20040137061A1 (en) | 2001-06-07 | 2004-07-15 | Takashi Ishibashi | Functional grain-containing preparations quickly disintegrated in the oral cavity |
GB0204771D0 (en) | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Fast disintegrating tablets |
-
2004
- 2004-01-20 EP EP04703478A patent/EP1595533B1/en not_active Expired - Lifetime
- 2004-01-20 WO PCT/JP2004/000444 patent/WO2004064810A1/ja active Application Filing
- 2004-01-20 AT AT04703478T patent/ATE454132T1/de not_active IP Right Cessation
- 2004-01-20 JP JP2005508095A patent/JP4475233B2/ja not_active Expired - Lifetime
- 2004-01-20 KR KR1020057013314A patent/KR101099176B1/ko active IP Right Grant
- 2004-01-20 DE DE602004024960T patent/DE602004024960D1/de not_active Expired - Lifetime
- 2004-01-20 KR KR1020117027321A patent/KR20110133060A/ko not_active Application Discontinuation
- 2004-01-20 US US10/542,969 patent/US8580305B2/en not_active Expired - Lifetime
-
2008
- 2008-07-10 US US12/170,859 patent/US20080299192A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0361874A2 (en) * | 1988-09-27 | 1990-04-04 | Takeda Chemical Industries, Ltd. | Granules having core and their production |
JPH08143473A (ja) * | 1994-11-22 | 1996-06-04 | Tanabe Seiyaku Co Ltd | 易服用性の有核錠型製剤 |
JP2001039861A (ja) * | 1999-07-30 | 2001-02-13 | Eisai Co Ltd | 薬物の放出を制御した速崩錠及びその製法 |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5004236B2 (ja) * | 2005-02-09 | 2012-08-22 | キッセイ薬品工業株式会社 | 口腔内崩壊錠 |
WO2007052289A2 (en) * | 2005-07-22 | 2007-05-10 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
US9198862B2 (en) | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
EP1906937B1 (en) | 2005-07-22 | 2016-10-19 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
WO2007052289A3 (en) * | 2005-07-22 | 2007-12-27 | Rubicon Res Pvt Ltd | Novel dispersible tablet composition |
EP1951203A4 (en) * | 2005-11-14 | 2011-07-06 | Teijin Pharma Ltd | COMPRESSED QUICKLY DISINTEGRATION ORALLY |
US9511029B2 (en) | 2005-11-14 | 2016-12-06 | Teijin Pharma Limited | Intraorally rapidly disintegrating tablet |
WO2007055428A1 (en) * | 2005-11-14 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Intraorally rapidly disintegrating tablet |
CN101309672B (zh) * | 2005-11-14 | 2015-07-29 | 帝人制药株式会社 | 口腔内快速崩解的片剂 |
JP2009515871A (ja) * | 2005-11-14 | 2009-04-16 | 帝人ファーマ株式会社 | 口腔内速崩性錠剤 |
WO2007055427A1 (en) | 2005-11-14 | 2007-05-18 | Teijin Pharma Limited | Intraorally rapidly disintegrating tablet |
EP1951203A1 (en) * | 2005-11-14 | 2008-08-06 | Teijin Pharma Limited | Intraorally rapidly disintegrating tablet |
JP2007153887A (ja) * | 2005-11-14 | 2007-06-21 | Teijin Pharma Ltd | アンブロキソール口腔内速崩性錠剤 |
US10300021B2 (en) | 2005-11-14 | 2019-05-28 | Teijin Pharma Limited | Intraorally rapidly disintegrating tablet |
AU2006312566B2 (en) * | 2005-11-14 | 2012-04-12 | Teijin Limited | Intraorally rapidly disintegrating tablet |
JP4934144B2 (ja) * | 2005-11-14 | 2012-05-16 | 帝人ファーマ株式会社 | 口腔内速崩性錠剤 |
JP2008127320A (ja) * | 2006-11-20 | 2008-06-05 | Zensei Yakuhin Kogyo Kk | 口腔内速崩壊性固形製剤 |
US9980915B2 (en) | 2007-03-13 | 2018-05-29 | Sumitomo Dainippon Pharma Co., Ltd. | Oral disintegrating tablet |
JPWO2008120548A1 (ja) * | 2007-03-13 | 2010-07-15 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
JP5537927B2 (ja) * | 2007-03-13 | 2014-07-02 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
US8778392B2 (en) | 2007-03-13 | 2014-07-15 | Dainippon Sumitomo Pharma Co., Ltd. | Oral disintegrating tablet |
WO2008120548A3 (ja) * | 2007-03-13 | 2008-12-18 | Dainippon Sumitomo Pharma Co | 口腔内崩壊錠 |
WO2009041651A1 (ja) | 2007-09-27 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | 速崩壊性固形製剤 |
JP2010095490A (ja) * | 2008-10-20 | 2010-04-30 | Nipro Corp | 錠剤の製造方法 |
US9387167B2 (en) | 2009-10-01 | 2016-07-12 | Adare Pharmaceuticals, Inc. | Orally administered corticosteroid compositions |
US10632069B2 (en) | 2009-10-01 | 2020-04-28 | Adare Pharmaceuticals Us, L.P. | Orally administered corticosteroid compositions |
US9486407B2 (en) | 2009-10-01 | 2016-11-08 | Adare Pharmaceuticals, Inc. | Orally administered corticosteroid compositions |
JP2013506683A (ja) * | 2009-10-01 | 2013-02-28 | アプタリス ファーマテク,インコーポレイテッド | 経口投与型コルチコステロイド組成物 |
JP2017036306A (ja) * | 2009-10-01 | 2017-02-16 | アデア ファーマスーティカルズ,インコーポレイテッド | 経口投与型コルチコステロイド組成物 |
JP2022078275A (ja) * | 2009-10-01 | 2022-05-24 | アデア ファーマスーティカルズ,インコーポレイテッド | 経口投与型コルチコステロイド組成物 |
US11246828B2 (en) | 2009-10-01 | 2022-02-15 | Ellodi Pharmaceuticals, L.P. | Orally administered corticosteroid compositions |
US9849084B2 (en) | 2009-10-01 | 2017-12-26 | Adare Pharmaceuticals, Inc. | Orally administered corticosteroid compositions |
JP2012046454A (ja) * | 2010-08-27 | 2012-03-08 | Lion Corp | 内服用錠剤およびその製造方法 |
WO2012144519A1 (ja) * | 2011-04-18 | 2012-10-26 | 出光興産株式会社 | 液体投与型粒剤 |
CN103491972A (zh) * | 2011-04-18 | 2014-01-01 | 出光兴产株式会社 | 液体给药型颗粒剂 |
US11166961B2 (en) | 2013-09-06 | 2021-11-09 | Ellodi Pharmaceuticals, L.P. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
US11260061B2 (en) | 2013-09-06 | 2022-03-01 | Ellodi Pharmaceuticals, L.P. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
US10471071B2 (en) | 2013-09-06 | 2019-11-12 | Adare Pharmaceuticals, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
JP2017119692A (ja) * | 2015-12-28 | 2017-07-06 | 日本新薬株式会社 | 圧縮成型製剤 |
WO2017115764A1 (ja) * | 2015-12-28 | 2017-07-06 | 日本新薬株式会社 | 圧縮成型製剤 |
JPWO2018003762A1 (ja) * | 2016-06-28 | 2019-04-18 | 株式会社日本抗菌総合研究所 | 賦形剤及び錠剤 |
JP7020688B2 (ja) | 2016-06-28 | 2022-02-16 | 株式会社日本抗菌総合研究所 | 賦形剤及び錠剤 |
JP2022051776A (ja) * | 2016-06-28 | 2022-04-01 | 株式会社日本抗菌総合研究所 | 賦形剤及び錠剤 |
JP7239119B2 (ja) | 2016-06-28 | 2023-03-14 | 株式会社日本抗菌総合研究所 | 賦形剤及び錠剤 |
US11026887B2 (en) | 2016-08-18 | 2021-06-08 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
US10105315B2 (en) | 2016-08-18 | 2018-10-23 | Adare Pharmaceuticals, Inc. | Methods of treating eosinophilic esophagitis |
US11684571B2 (en) | 2016-08-18 | 2023-06-27 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
US11896710B2 (en) | 2016-08-18 | 2024-02-13 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
US12059494B2 (en) | 2016-08-18 | 2024-08-13 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
Also Published As
Publication number | Publication date |
---|---|
KR101099176B1 (ko) | 2011-12-27 |
US8580305B2 (en) | 2013-11-12 |
JP4475233B2 (ja) | 2010-06-09 |
US20080299192A1 (en) | 2008-12-04 |
EP1595533B1 (en) | 2010-01-06 |
US20060134199A1 (en) | 2006-06-22 |
KR20050096941A (ko) | 2005-10-06 |
EP1595533A1 (en) | 2005-11-16 |
KR20110133060A (ko) | 2011-12-09 |
JPWO2004064810A1 (ja) | 2006-05-18 |
DE602004024960D1 (de) | 2010-02-25 |
ATE454132T1 (de) | 2010-01-15 |
EP1595533A4 (en) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004064810A1 (ja) | 口腔内速崩性錠剤 | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
ES2347968T3 (es) | Preparacion solida que se disgrega rapidamente. | |
ES2393640T3 (es) | Comprimidos bucodisgregables | |
JP5053865B2 (ja) | 口腔内崩壊性固形製剤の製造法 | |
JP4920798B2 (ja) | 2種以上の粒子を含有する口腔内速崩壊錠 | |
JP2009114113A (ja) | 口腔内崩壊錠及びその製造方法 | |
AU2004229177A1 (en) | Orally disintegrating tablets | |
CN108969490A (zh) | 快速分散颗粒、口腔崩解片以及方法 | |
JP5405752B2 (ja) | 被覆された薬物含有粒子および該粒子を含む固形製剤 | |
EP2540318B1 (en) | Sustained-release solid preparation for oral use | |
JP2013006798A (ja) | 粒子製剤の製造方法 | |
JP5572321B2 (ja) | 被覆微粒子含有口腔内崩壊錠 | |
JP5807642B2 (ja) | アトルバスタチン含有医薬錠剤 | |
WO2019230937A1 (ja) | 溶出性に優れた経口固形製剤 | |
EP3733166A1 (en) | Cyclic orally disintegrating tablet | |
WO2018124282A1 (ja) | 医薬組成物およびその製造方法 | |
TW200529885A (en) | Antifungal oral dosage forms and the methods for preparation | |
JP7547723B2 (ja) | アビラテロン酢酸エステル含有製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005508095 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004703478 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057013314 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006134199 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10542969 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057013314 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004703478 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10542969 Country of ref document: US |